Impact of Coronavirus Diseases on Liver Enzymes

Ammara Naeem 1, Manoj Kumar Khumani 2, Pardeep Kumar 2, FNU Pooja 3, Deepak Raj 2, Kirshan Lal 4, Wajeefa Shahid 5, Waseem Mahar 6, Amber Rizwan 7, Aliya Fatima 8

1. Internal Medicine, Lahore General Hospital, Lahore, PAK. 2. Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK. 3. Internal Medicine, Chandika Medical College, Larkana, PAK. 4. Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK. 5. Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK. 6. Internal Medicine, Ghulam Muhammad Mahar Medical College, Karachi, PAK. 7. Family Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK. 8. Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.

Corresponding author: Amber Rizwan, amber_aljazeera109@hotmail.com

Abstract

Introduction

Coronavirus disease 2019 (COVID-19) affects various organs including lungs, brain, and eyes. Very limited data is available related to the effect of COVID-19 on liver. This study is conducted to determine the impact of COVID-19 on liver by measuring the frequency of participants with deranged liver enzymes in patients diagnosed with COVID-19.

Methods

This cross-sectional study was conducted in a COVID-19 unit of a tertiary care hospital in Pakistan from February 2021 to June 2021. A total of 900 patients admitted with COVID-19 were enrolled in the study after seeking informed consent. After enrollment, taking history and vitals, 5 mL blood was drawn via phlebotomy and sent to the laboratory to test for C-reactive protein, lactate dehydrogenase, and liver enzymes.

Results

Overall 141 (28.2%) participants had a minimum of one deranged liver enzyme. The most commonly deranged liver enzyme found was alanine transaminase (ALT), both in males (19.9%) and females (21.3%), followed by aspartate transaminase (male: 18.3% and female: 20.3%). Serum total bilirubin was deranged in both males (8.4%) and females (8.3%). There was no significant difference in the gender-wise prevalence of deranged liver enzymes.

Conclusion

Liver enzymes are frequently deranged in patients admitted with COVID-19. Liver enzymes should be regularly monitored during the course of management of COVID-19, as various medications used in the treatment of COVID-19 may further deteriorate liver enzymes and may cause long-term damage.

Categories: Internal Medicine, Gastroenterology, Infectious Disease
Keywords: covid-19, novel corona virus, liver enzymes, hepatic enzymes, sars-cov-2 (severe acute respiratory syndrome coronavirus -2)

Introduction

Around the globe, healthcare systems have faced immense challenges due to the coronavirus disease 2019 (COVID-19) pandemic [1]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the Coronaviridae family of the virus and betacoronavirus genus. SARS-CoV-2 and the Middle East respiratory syndrome–related coronavirus (MERS-CoV) also belong to the family Coronaviridae [2].

Fever, cough, dyspnea, and chest pain are the symptoms commonly reported in cases of COVID-19. Ground-glass opacities are seen on radiological investigations, suggesting pneumonia [3]. Other than conventional symptoms, many other organs are affected as well by COVID-19. The frequency of neurological symptoms in COVID-19 cases is appreciable. Mostly the neurological symptoms reported are dizziness, headache, impairment of taste and smell [4]. In patients with COVID-19, ophthalmological symptoms were also found. The most common of those symptoms is conjunctival irritation, followed by diplopia and cotton wool spots [5]. The long-term impact of COVID-19 has been identified. Top five symptoms reported are fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%) [6].

The impact of COVID-19 on the function of the liver is under-studied and there is insufficient data regarding the impact of COVID-19 on liver enzymes. Therefore, this study is conducted to determine the presence of deranged liver enzymes in patients diagnosed with COVID-19.

How to cite this article
Naeem A, Khumani M, Kumar P, et al. (September 01, 2021) Impact of Coronavirus Diseases on Liver Enzymes. Cureus 13(9): e17650. DOI 10.7759/cureus.17650
Materials And Methods

This cross-sectional study was conducted in a COVID-19 unit of a tertiary care hospital in Pakistan from February 2021 to June 2021. Total 900 patients, admitted with COVID-19, were enrolled in the study after seeking informed consent. Participants were enrolled via consecutive convenient non-probability sampling. Participants were explained about research protocol and any queries were addressed. Ethical review board approval was taken from Liaquat University of Medical Health Sciences (LUMHS/2021/COVID/IRB-04) before the enrollment of patients. Sample for COVID-19 was taken via nasal swap. COVID-19 was diagnosed by polymerase chain reaction. Patients with a history of liver disease, recent hepatitis, gallstones, or on drugs that affect liver enzymes were excluded from the study.

After enrollment, the patient’s vitals such as respiratory rate and oxygen saturation were noted in the questionnaire, and 5 mL blood was drawn via phlebotomy and sent to the same laboratory to test for C-reactive protein (CRP), lactate dehydrogenase (LDH), and liver enzymes. All tests were conducted from the same laboratory to maintain consistency.

SPSS Statistics, v. 23.0 (IBM Corporation, Armonk, New York, United States) was used to analyze the collected data. For numerical data, mean and standard deviation (SD) were calculated, while frequency and percentage were calculated for categorical data. Independent t-test and chi-square were used when deemed appropriate. A p-value of less than 0.05 indicated a statistically significant difference between the two groups and the null hypothesis is void.

Results

The mean age of participants at the time of admission was 46 ± 07 years. There were 261 (52.2%) males and 239 (47.8%) females. CRP value was 110.7 ± 14.3 mg/dL and mean SaO2 was 88.2 ± 4.3% at the time of admission. Other demographics are defined in Table 1.

| Characteristics at the time of admission | Value |
|------------------------------------------|-------|
| Age (in years)                           | 46 ± 07|
| Male                                     | 261 (52.2%) |
| Temperature (°F)                         | 100.6 ± 0.7 |
| Respiratory Rate (BPM)                   | 30.6 ± 4.9 |
| CRP (mg/dL)                              | 110.7 ± 14.3 |
| LDH (IU)                                 | 325.6 ± 87.5 |
| SaO2 (%)                                 | 88.2 ± 4.3 |

TABLE 1: Characteristics of study participants

BPM: breaths per minute, CRP: C-reactive protein, °F: Fahrenheit, IU: international unit, LDH: lactate dehydrogenase, mg/dL: milligram per decilitre, SaO2: Oxygen saturation

The mean alanine transferase (ALT) values in males and females were 62.51 ± 32.01 IU and 42.14 ± 15.14 IU, respectively. The mean gamma-glutamyl transferase (GGT) value in males was 52.21 ± 28.21 IU and 45.26 ± 19.72 IU in females. Serum total bilirubin in males was 12.14 ± 3.59 umol/L and in females, it was 13.17 ± 3.59 umol/L (Table 2).
### Mean liver enzyme values

| Enzyme                        | Normal Laboratory Range | Our Study Male (n=261) | Our Study Female (n=239) |
|-------------------------------|-------------------------|------------------------|--------------------------|
| Serum total bilirubin (umol/L)| 1.71-20.52              | 12.14 ± 3.59           | 13.17 ± 3.59             |
| Serum direct bilirubin (umol/L)| 0-3.42                  | 1.54 ± 0.34            | 1.54 ± 0.17              |
| Serum indirect bilirubin (umol/L)| 1.71-13.68           | 10.62 ± 2.05           | 10.09 ± 1.88             |
| Serum GGT (IU)                | Male: < 55, Female: < 38| 52.21 ± 28.21          | 45.26 ± 19.72            |
| ALT (IU)                      | Male: < 45, Female: < 35| 62.51 ± 32.01          | 42.14 ± 15.14            |
| AST (IU)                      | Male: < 35, Female: < 31| 35.02 ± 14.51          | 30.82 ± 13.21            |

### TABLE 2: Genderwise comparison of mean liver enzyme values

ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transferase, IU: international unit, umol/L: micromole per liter

| Enzyme                        | Male (n=261) | Female (n=239) | p-value |
|-------------------------------|--------------|----------------|---------|
| Serum total bilirubin (mg/dL)  | 22 (8.4%)    | 20 (8.3%)      | NS      |
| Serum direct bilirubin (mg/dL) | 26 (9.9%)    | 22 (9.2%)      | NS      |
| Serum indirect bilirubin (mg/dL)| 14 (5.3%)    | 12 (5.0%)      | NS      |
| Serum GGT (IU)                | 43 (16.4%)   | 38 (15.9%)     | NS      |
| ALT (IU)                      | 52 (19.9%)   | 51 (21.3%)     | NS      |
| AST (IU)                      | 48 (18.3%)   | 48 (20.3%)     | NS      |

### TABLE 3: Prevalence of deranged liver enzymes

ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transferase, IU: international unit, mg/dL: milligrams per decilitre, NS: nonsignificant

### Discussion

Our study demonstrated that 28.2% of participants had a minimum of one deranged liver enzyme. However, the most commonly deranged liver enzyme was ALT, both in males (19.9%) and females (21.3%), followed by AST (male: 18.3% and female: 20.3%). Serum total bilirubin was deranged in 8.4% of male participants and 8.3% of the female participants. There was no significant difference in the prevalence of deranged liver enzymes between males and females (Table 3).

Supporting the results of our study, the literature provides some large-scale studies that assessed the clinical features of COVID-19 patients and some factors that could potentially lead to liver injury caused by COVID-19. In these studies, higher levels of ALT and AST were observed[7-10]. Several case reports have also shown abnormal liver function tests (LFTs) in patients with COVID-19[7,11,12]. In a study, patients grouped based on the severity of the disease indicated that severe COVID-19 patients had higher levels of ALT and AST compared to those with mild disease[9,15,14].

The theory that might explain the effect of COVID-19 on liver is related to presence of angiotensin-converting enzyme 2 receptors. As angiotensin-converting enzyme 2 receptors are expressed on cholangiocytes, COVID-19 can conveniently attack the liver. While examining the liver of COVID-19 patients, endothelitis was noticed[15], and liver sinusoids showed fibrin microthrombi[16]. When 48 cases
of liver biopsies were studied, liver sinusoids demonstrated dilatation of portal vein branches, luminal thrombosis, portal tract fibrosis, and microthrombi in the sinusoids [17].

In view of the above-mentioned literature, higher levels of liver enzymes are observed in critical COVID-19 patients. Cai et al. stated that with the administration of lopinavir–ritonavir, changes in LFTs are expected to increase seven times [18]. Similarly, a clinical trial conducted on 199 patients with severe COVID-19 demonstrated that increases in ALT, AST, and total bilirubin levels were more often observed in the lopinavir–ritonavir group compared to those who did not receive this. Remdesivir has also been reported to cause early recovery of COVID-19 patients [19]. In a trial assessing Remdesivir treatment for five or ten days, a considerable increase in ALT/AST levels was observed in 4-6% of patients as well as a life-threatening increase in 2-3% of patients, leading to the discontinuation of the treatment [20]. Acetaminophen, a drug used to treat COVID-19 symptoms, is known to cause fluctuations in aminotransferases even at normal doses [21]. Previous data is not available on the relation between hydroxychloroquine and its effect on LFTs [22,23].

This study points towards the idea that COVID-19 patients should be screened for liver enzymes at regular intervals for better management of the disease. However, since it is a single-center study, future studies involving multiple centers with a larger sample size are required to confirm the findings of our study.

Conclusions
Liver enzymes are frequently deranged in patients admitted with COVID-19. Liver enzymes should be regularly monitored during the course of management of COVID-19, as various medications used in the treatment of COVID-19 may further deteriorate liver enzymes and may cause long-term damage. Moreover, proper screening of liver enzymes would also help in better treatment of patients with underlying liver conditions to minimize the chances of further complications.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Liaquat University of Medical and Health Sciences issued approval LUMHS/2021/COVID/IRB-04. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Rodríguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al.: Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020, 34:101623. 10.1016/j.medi.2020.101625
2. Harapan H, Ioh N, Yufika A, et al.: Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020, 13:567-73. 10.1016/j.jiph.2020.05.019
3. Frediansyah A, Nainu F, Dharma K, Madatir M, Harapan H: Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health. 2021, 9:125-7. 10.1016/j.cefgh.2020.07.011
4. Makida A, Kumar S, Kumar A, Kumar V, Rizwan A: The frequency of neurological symptoms in COVID-19 patients at a tertiary care hospital in Pakistan. Cureus. 2020, 12:e10360. 10.7759/cureus.10360
5. Khan SI, Versha F, Bai P, et al.: Frequency of ophthalmological findings in hospitalized COVID-19 patients. Cureus. 2021, 13:e14942. 10.7759/cureus.14942
6. Lopez-Leon S, Wegman-Östrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S: More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis (PREPRINT). medRxiv. 2021, 10.1101/2021.01.27.21250617
7. Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016/S0140-6736(20)30211-7
8. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016/S0140-6736(20)30183-5
9. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-20. 10.1056/NEJMoa2002052
10. Wang D, Hu B, Hu C, et al.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020, 323:1061-9. 10.1001/jama.2020.1585
11. Weber S, Mayerle J, Irbeek M, Gerbes AL: Severe liver failure during SARS-CoV-2 infection. Gut. 2020, 69:1365-7. 10.1136/gutjnl-2020-321550
12. Wander P, Epstein M, Bernstein D: COVID-19 presenting as acute hepatitis. Am J Gastroenterol. 2020, 115:941-4. 10.14309/aig.0000000000000660
13. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q: Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020, 40:2095-103.
14. Wang Z, Yang B, Li Q, Wen L, Zhang R: Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020, 71:769-77. 10.1093/cid/ciaa272

15. Varga Z, Flammer AJ, Steiger P, et al.: Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395:1417-8. 10.1016/S0140-6736(20)30937-5

16. Duarte-Neto AN, Monteiro RA, da Silva LF, et al.: Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. Histopathology. 2020, 77:186-97. 10.1111/his.14160

17. Sonzogni A, Previtali G, Seghezzi M, et al.: Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020, 40:2110-6. 10.1111/liv.14601

18. Cai Q, Huang D, Yu H, et al.: COVID-19: Abnormal liver function tests. J Hepatol. 2020, 73:566-74. 10.1016/j.jhep.2020.04.006

19. Beigel JH, Tomashek KM, Dodd LE, et al.: Remdesivir for the treatment of COVID-19- final report. N Engl J Med. 2020, 383:1813-26. 10.1056/NEJMoa2007764

20. Goldman JD, Lye DC, Hui DS, et al.: Remdesivir for 5 or 10 days in patients with severe COVID-19 . N Engl J Med. 2020, 383:1827-37. 10.1056/NEJMoa2015301

21. Acetaminophen - LiverTox: clinical and research information on drug-induced liver injury . (2012). Accessed: July 10, 2021: https://www.ncbi.nlm.nih.gov/books/NBK548162/

22. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM: Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020, 173:287-96. 10.7326/M20-2496

23. Borba MG, Val FF, Sampaio VS, et al.: Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020, 3:e208857. 10.1001/jamanetworkopen.2020.8857